Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. - Wikidata - awgldk - TriplyDB

Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.

Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q35601541

about

Gut Microbiota and Lifestyle Interventions in NAFLD Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.Inflammation: The Common Pathway of Stress-Related Diseases.Effects of taurine supplementation on hepatic markers of inflammation and lipid metabolism in mothers and offspring in the setting of maternal obesity.Oxidative stress-mediated aldehyde adduction of GRP78 in a mouse model of alcoholic liver disease: functional independence of ATPase activity and chaperone function.Elongation Factor 1A-1 Is a Mediator of Hepatocyte Lipotoxicity Partly through Its Canonical Function in Protein Synthesis The role of visceral and subcutaneous adipose tissue fatty acid composition in liver pathophysiology associated with NAFLD.Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice.Taurine drinking ameliorates hepatic granuloma and fibrosis in mice infected with Schistosoma japonicum Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea pigs Oral nitrite therapy improves vascular function in diabetic mice Taurine and liver diseases: a focus on the heterogeneous protective properties of taurine.The role of antioxidants and other agents in alleviating hyperglycemia mediated oxidative stress and injury in liver.The unfolded protein response in fatty liver disease.Role of taurine in the pathogenesis of obesity.Early life programming and the risk of non-alcoholic fatty liver disease.Fuzhuan tea consumption imparts hepatoprotective effects and alters intestinal microbiota in high saturated fat diet-fed rats.Fructose-induced stress signaling in the liver involves methylglyoxal.Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats.Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model.Hepatoprotective effect of calculus bovis sativus on nonalcoholic fatty liver disease in mice by inhibiting oxidative stress and apoptosis of hepatocytes.Naltrexone changes the expression of lipid metabolism-related proteins in the endoplasmic reticulum stress induced hepatic steatosis in mice.The Effect of Amygdalin on Endoplasmic Reticulum (ER) Stress Induced Hepatic Steatosis in Mice.

P2860

Q26749783-BD044329-26A7-4044-8542-DEB39DE8CE38 Q28831365-D960D6A2-5791-4DD8-AAEC-FB29FB1C6157 Q30412771-347A0A82-76B6-4B86-BCB2-988776E67065 Q33813364-C91040A3-F65C-4638-87B3-5D50686A5878 Q35023011-F790E1DA-E853-4AAA-B06B-5296D752FCA1 Q35394551-180BBB83-1D03-4942-895B-C254C8257DDA Q35671675-6E9BE8F9-5029-4B22-9AAF-619DA6F251A0 Q35834720-6C0D0728-D3B4-42A4-BD55-12A598EB79E9 Q35998233-1FCA4133-448B-416E-88C4-201040836FA5 Q36724076-DFED3A8B-BFBF-4549-83E9-3A9A3863271D Q36769334-337652F7-99CC-4769-9125-E5119B397F17 Q37163653-81E13816-3BCB-41E0-9403-D55ACCEEAECF Q37263349-CC798FE9-93A5-40FB-920F-0ECE826768E4 Q38037378-2DE2FF56-BAFB-47CB-B27F-6794D695103F Q38113967-81EBCA91-3669-4060-870A-B1BA0B024271 Q38162132-433C4978-4A32-470F-A776-8D94166E60D2 Q38383117-A44A02D8-31A9-41DE-8AE8-C64F83004030 Q39006023-60E34731-0D2A-4AC9-BB9A-40762A8F9545 Q39987945-84EC8A0F-B9F8-48C1-9C67-59F7C3076AEF Q40101092-AA1E3E77-E346-4D87-80A5-73B96092EC2C Q41467690-28B6C241-6FA7-4FF1-B3B4-B92F578D73BE Q42614530-EE238B4E-B8CD-4607-BDC8-5AF0DB1BF098 Q46237033-F8C994C1-6D5F-4C0B-ADAE-88EE6703B3C2 Q51076739-B851465F-17AE-4EB7-AEFD-0EA2CCCE43F7 Q54945589-E39DB76A-4A03-444A-ABAB-6649DF7640AE

P2860

Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q35601541

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Experimental evidence for ther ...... alcoholic fatty liver disease.

@ast

Experimental evidence for ther ...... alcoholic fatty liver disease.

@en

type

label

Experimental evidence for ther ...... alcoholic fatty liver disease.

@ast

Experimental evidence for ther ...... alcoholic fatty liver disease.

@en

prefLabel

Experimental evidence for ther ...... alcoholic fatty liver disease.

@ast

Experimental evidence for ther ...... alcoholic fatty liver disease.

@en

P1433

Q35601541-E7251023-DF81-484D-8830-DC0E061599E1

P1476

Q35601541-1A4B3935-50F9-4CF6-8A4E-08D96EB8D0E3

P2093

Q35601541-013EAC2C-4EE4-404D-A856-7AFF83B547C3

Q35601541-0927F7C3-BD70-41D4-A831-6A9271DD023C

Q35601541-2C0A0753-0450-481A-B59A-20E026B5F81E

Q35601541-40431EA5-07E5-44F8-8304-FE0B2B59C44D

Q35601541-73451737-D581-478D-9A67-61D8091449DB

Q35601541-79480246-A5E4-4287-8633-5B6D47EA2191

Q35601541-A218D7EE-EBFF-4EA4-80E7-8D501F4866CE

Q35601541-AA23138A-82EB-4B4D-8E8F-C0DE352A8D6A

Q35601541-C71DD0AD-9C9A-4F53-A128-1D98AC74CBC5

Q35601541-C98EF188-1386-4116-8EEA-C14BF0AE4713

P2860

Q35601541-00CB991F-E9DF-4F10-A441-893035977539

Q35601541-010EAC89-BABA-4AF8-8704-419170273F39

Q35601541-02062686-BFFB-440E-82A6-951953502A53

Q35601541-033F15D3-6A76-48C5-BF84-4AA2DE2507B3

Q35601541-046CC75C-A5AD-4B43-B7DB-205C0DA4A087

Q35601541-081B93B3-3408-4A78-95E6-64646A9081AD

Q35601541-0B6D45EF-CD88-4714-A1F5-B6DA74B6BDBE

Q35601541-0BE8AF75-C66D-44F9-B5B0-5E24E7E01F2B

Q35601541-0C310223-F7A9-4A8D-BC8D-9DA564FBF3FA

Q35601541-16FBFB73-260D-4BB7-9C2C-A0CD9DB01EFE

P304

Q35601541-C5FE2258-C622-44CB-B660-424A8CE91135

P31

Q35601541-1D8D2652-F200-4DFB-80F4-10C960B8346A

P356

Q35601541-CE2D447C-29B3-4E50-8C8A-8D72E9DEBD62

P433

Q35601541-76827999-82DE-4DB7-B804-181ECAC6A54D

P478

Q35601541-21CB1060-53CE-43A5-B151-B3355E2A060A

P577

Q35601541-DF328F24-CC29-4D4D-AF25-619868268B00

P5875

Q35601541-9C74817F-ECEC-4A88-A592-DD90BDF5C860

P698

Q35601541-573B73DE-3E56-4C7F-860A-75E6243DE8F7

P932

Q35601541-5D2A59E2-D16D-4D3A-9B14-EF3F0D1B2EDA

P356

AJPREGU.00677.2010

P1433

American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

P1476

Experimental evidence for ther ...... alcoholic fatty liver disease.

@en

P2093

Angela M Nivala

http://www.w3.org/2001/XMLSchema#string

Christopher L Gentile

http://www.w3.org/2001/XMLSchema#string

David J Orlicky

http://www.w3.org/2001/XMLSchema#string

Dennis R Petersen

http://www.w3.org/2001/XMLSchema#string

Dong Wang

http://www.w3.org/2001/XMLSchema#string

Hua Jiang

http://www.w3.org/2001/XMLSchema#string

Jon C Gonzales

http://www.w3.org/2001/XMLSchema#string

Kenneth N Maclean

http://www.w3.org/2001/XMLSchema#string

Kyle T Pfaffenbach

http://www.w3.org/2001/XMLSchema#string

Michael J Pagliassotti

http://www.w3.org/2001/XMLSchema#string

P2860

Endoplasmic reticulum stress and the inflammatory basis of metabolic disease

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma

Protein carbonylation, cellular dysfunction, and disease progression

Regulation of hepatic lipogenesis by the transcription factor XBP1

CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum

Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes

Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

P304

R1710-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPREGU.00677.2010

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

301

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51679571

http://www.w3.org/2001/XMLSchema#string

P698

21957160

http://www.w3.org/2001/XMLSchema#string

P932

3233850

http://www.w3.org/2001/XMLSchema#string